Compared with CKD stage 3a, CKD stages 3b, 4, and 5 were associated with significant 1.5-, 2.4-, and 5.4-fold increased risks of anemia.
In a study, a 1 g/dL reduction in hemoglobin was associated with a significant 1.8-fold increase in graft failure.
Investigators observed a dose-related increase in hemoglobin over 6 weeks compared with placebo.
In a study, hemoglobin values of less than 14 g/dL in men or 12 g/dL in women were associated with greater risk for end-stage renal disease.
In a study of veterans with nondialysis CKD, patients with functional iron deficiency had the highest mortality risk.
High platelet counts and anemia are among the risk factors for arteriovenous fistula dysfunction in patients on hemodialysis.
Even a low HAS-BLED score of 0 was associated with high risk for bleeding in this population: 5.6 per 100 patient-years.
In hemodialysis patients with high ferritin levels at baseline, the iron-based phosphate binder ferric citrate increased mean transferrin saturation from 23.6% to 36.1% at 90 days.
In a nationwide study of Japanese hemodialysis patients, long-acting ESA use was associated with increased rates of cardiovascular and noncardiovascular mortality compared with short-acting ESA use.
The physician, who was experiencing an osteoarthritis flare following steroid therapy, began self-treating with turmeric extract capsules.